Cochrane · systematic review · CD011952
Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease
Gess, B, Baets, J, De Jonghe, P, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 33.3%High 4 · 66.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: adults with CMT1A
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Impairment ‐ change in CMTNS at 24 months (0 to 36 points) | no estimate extracted | 3 studies · 388 participants | High |
Impairment ‐ change in CMTES at 24 months (0 to 28 points) | no estimate extracted | 2 studies · 337 participants | Moderate |
Change in timed 10‐m walk at 12 months (seconds (s)) | no estimate extracted | 3 studies · 401 participants | High |
Change in foot dorsiflexion at 12 months (N) | no estimate extracted | 4 studies · 423 participants | High |
Change in 9‐hole peg test (HPT) at 12 months (seconds) | no estimate extracted | 3 studies · 286 participants | Moderate |
Serious adverse events (SAE; %) | no estimate extracted | 1 study · 702 participants | High |